31 July 2026हिंदी में पढ़ेंहिं
TODAY
57th GST Council meeting rescheduled to October 7India GDP grows 7.8%; PM urges less gold buying, foreign travelCoal Ministry rejects 'no takers' claim on gasification schemeJapan's JCR upgrades India's sovereign rating to A-India, China hold first Corps Commander meeting in ArunachalUN backs map showing Africa's true sizeIndia Services PMI rises to 54.1 in AugustIIP growth slows to 6.7% in July 2026ISRO won't be 'diminished', says IN-SPACe chairman
Today›31 July 2026
HealthJaved Anees · CC0
Science & Technology

India’s first dengue vaccine arrives with a crucial safety caveat

India's first dengue vaccine, Qdenga, has become available but with a significant safety caveat. In children who have never had a dengue infection, the vaccine can simulate a primary infection, conferring protection against DENV-1 and DENV-2 but not DENV-3, and potentially enhancing later DENV-3 disease. This makes prior-infection status central to who benefits.

Nabka Insight

India's first dengue vaccine and its serotype-specific caveat are topical science-and-technology material.

Powered by AI

Key facts

  • Qdenga is India's first dengue vaccine.
  • In previously uninfected children it protects against DENV-1 and DENV-2 but not DENV-3.
  • The vaccine may enhance dengue in children who have not had a prior infection.

Relevant forRailways · SSC · State PSC · UPSC

← Full digest